128 related articles for article (PubMed ID: 37639742)
1. USP8 promotes gemcitabine resistance of pancreatic cancer via deubiquitinating and stabilizing Nrf2.
Cui J; Guo Y; Yin T; Gou S; Xiong J; Liang X; Lu C; Peng T
Biomed Pharmacother; 2023 Oct; 166():115359. PubMed ID: 37639742
[TBL] [Abstract][Full Text] [Related]
2. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
[TBL] [Abstract][Full Text] [Related]
3. Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway.
Zhou Y; Zhou Y; Yang M; Wang K; Liu Y; Zhang M; Yang Y; Jin C; Wang R; Hu R
Redox Biol; 2019 Apr; 22():101131. PubMed ID: 30735911
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases.
Zhu Y; Xu J; Hu W; Wang F; Zhou Y; Gong W; Xu W
Aging (Albany NY); 2021 Jun; 13(11):14999-15012. PubMed ID: 34081623
[TBL] [Abstract][Full Text] [Related]
5. USP8 prevents aberrant NF-κB and Nrf2 activation by counteracting ubiquitin signals from endosomes.
Endo A; Fukushima T; Takahashi C; Tsuchiya H; Ohtake F; Ono S; Ly T; Yoshida Y; Tanaka K; Saeki Y; Komada M
J Cell Biol; 2024 Mar; 223(3):. PubMed ID: 38180476
[TBL] [Abstract][Full Text] [Related]
6. The oncogenic role of ubiquitin specific peptidase (USP8) and its signaling pathways targeting for cancer therapeutics.
Islam MT; Chen F; Chen H
Arch Biochem Biophys; 2021 Apr; 701():108811. PubMed ID: 33600786
[TBL] [Abstract][Full Text] [Related]
7. The ubiquitin-specific protease USP8 directly deubiquitinates SQSTM1/p62 to suppress its autophagic activity.
Peng H; Yang F; Hu Q; Sun J; Peng C; Zhao Y; Huang C
Autophagy; 2020 Apr; 16(4):698-708. PubMed ID: 31241013
[TBL] [Abstract][Full Text] [Related]
8. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer.
Fang Y; Zhou W; Rong Y; Kuang T; Xu X; Wu W; Wang D; Lou W
Exp Cell Res; 2019 Oct; 383(1):111543. PubMed ID: 31374207
[TBL] [Abstract][Full Text] [Related]
9. Deubiquitinase USP8 increases ID1 stability and promotes esophageal squamous cell carcinoma tumorigenesis.
Li L; Liu Y; Zhao Y; Feng R; Li Y; Yu X; Liu Z; Wang L
Cancer Lett; 2022 Aug; 542():215760. PubMed ID: 35636624
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme.
Panner A; Crane CA; Weng C; Feletti A; Fang S; Parsa AT; Pieper RO
Cancer Res; 2010 Jun; 70(12):5046-53. PubMed ID: 20484045
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitin-specific protease 8 (USP8/UBPy): a prototypic multidomain deubiquitinating enzyme with pleiotropic functions.
Dufner A; Knobeloch KP
Biochem Soc Trans; 2019 Dec; 47(6):1867-1879. PubMed ID: 31845722
[TBL] [Abstract][Full Text] [Related]
12. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.
Liu DL; Bu H; Li H; Chen H; Guo HC; Wang ZH; Tong HF; Ni ZL; Liu HB; Lin SZ
Int J Oncol; 2012 Apr; 40(4):1049-57. PubMed ID: 22159556
[TBL] [Abstract][Full Text] [Related]
13. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer.
Fan K; Fan Z; Cheng H; Huang Q; Yang C; Jin K; Luo G; Yu X; Liu C
Cancer Med; 2019 Oct; 8(13):5903-5915. PubMed ID: 31426130
[TBL] [Abstract][Full Text] [Related]
14. USP8 is a novel target for overcoming gefitinib resistance in lung cancer.
Byun S; Lee SY; Lee J; Jeong CH; Farrand L; Lim S; Reddy K; Kim JY; Lee MH; Lee HJ; Bode AM; Won Lee K; Dong Z
Clin Cancer Res; 2013 Jul; 19(14):3894-904. PubMed ID: 23748694
[TBL] [Abstract][Full Text] [Related]
15. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
[TBL] [Abstract][Full Text] [Related]
16. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway.
Xiang Y; Ye W; Huang C; Yu D; Chen H; Deng T; Zhang F; Lou B; Zhang J; Shi K; Chen B; Zhou M
Oxid Med Cell Longev; 2018; 2018():2360427. PubMed ID: 29849873
[TBL] [Abstract][Full Text] [Related]
17. USP8 suppresses death receptor-mediated apoptosis by enhancing FLIP
Jeong M; Lee EW; Seong D; Seo J; Kim JH; Grootjans S; Kim SY; Vandenabeele P; Song J
Oncogene; 2017 Jan; 36(4):458-470. PubMed ID: 27321185
[TBL] [Abstract][Full Text] [Related]
18. USP8 promotes cancer progression and extracellular vesicle-mediated CD8+ T cell exhaustion by deubiquitinating the TGF-β receptor TβRII.
Xie F; Zhou X; Li H; Su P; Liu S; Li R; Zou J; Wei X; Pan C; Zhang Z; Zheng M; Liu Z; Meng X; Ovaa H; Ten Dijke P; Zhou F; Zhang L
EMBO J; 2022 Aug; 41(16):e108791. PubMed ID: 35811497
[TBL] [Abstract][Full Text] [Related]
19. The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
Song J; Xu J; Guo J; Shang Y; Wang J; Wang T
Acta Histochem; 2021 Sep; 123(6):151769. PubMed ID: 34416437
[TBL] [Abstract][Full Text] [Related]
20. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches.
Ashrafizadeh M; Luo K; Zhang W; Reza Aref A; Zhang X
Environ Res; 2024 Jan; 240(Pt 2):117443. PubMed ID: 37863168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
